试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-19
Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal
编号:NCT02823977登记状态:入组前撤回企业 / 申办者:University of Colorado, Denver
药物 / 成分:Ketamine、Dexmedetomidine、Normal saline
登记的停止原因(原文):Funding not obtained
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-19
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
编号:NCT03343847登记状态:入组前撤回企业 / 申办者:Amgen
药物 / 成分:Romiplostim、Placebo
登记的停止原因(原文):Study was not feasible
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-17
A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
编号:NCT01093170登记状态:入组前撤回企业 / 申办者:Mark Kleinman
药物 / 成分:RNA-144101
登记的停止原因(原文):Study was not conducted, no subjects recruited.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-17
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
编号:NCT02966587登记状态:入组前撤回企业 / 申办者:University of Washington
药物 / 成分:Durvalumab、Laboratory Biomarker Analysis
登记的停止原因(原文):Withdrawn prior to opening to enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-17
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
编号:NCT03205891登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Brentuximab Vedotin、TAK228、Glucose Monitor
登记的停止原因(原文):Change in treatment priorities for these disease types as well as staffing concerns.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-16
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
编号:NCT03108729登记状态:入组前撤回企业 / 申办者:Sumitomo Pharma America, Inc.
药物 / 成分:Eslicarbazepine acetate
登记的停止原因(原文):The study was not withdrawn for safety reasons. The sponsor received approval for the treatment of partial-onset seizures in patients 4 years of age and older
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-12
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
编号:NCT00615524登记状态:入组前撤回企业 / 申办者:GlaxoSmithKline
药物 / 成分:exemestane and pazopanib
登记的停止原因(原文):Cancelled Before Enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-12
Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill
编号:NCT02009943登记状态:入组前撤回企业 / 申办者:Denver Health and Hospital Authority
药物 / 成分:Ferric carboxymaltose、Iron sucrose
登记的停止原因(原文):Inadequate funds
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-12
The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy
编号:NCT02509182登记状态:入组前撤回企业 / 申办者:Yale University
药物 / 成分:60% oxygen、100% oxygen
登记的停止原因(原文):Study never officially began
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-12
Evaluation of Fluorescein Use During Cystoscopy
编号:NCT02703558登记状态:入组前撤回企业 / 申办者:Johns Hopkins University
药物 / 成分:Phenazopyridine、Fluorescein
登记的停止原因(原文):Limited interest from colleagues/time constraints
查看官方原始记录 ↗